As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
30 Analysts have issued a Tandem Diabetes Care, Inc. forecast:
30 Analysts have issued a Tandem Diabetes Care, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 1,007 1,007 |
18%
18%
|
|
| Gross Profit | 536 536 |
26%
26%
|
|
| EBITDA | -70 -70 |
41%
41%
|
|
| EBIT (Operating Income) EBIT | -87 -87 |
35%
35%
|
|
| Net Profit | -203 -203 |
60%
60%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | John Sheridan |
| Employees | 2,650 |
| Founded | 2006 |
| Website | www.tandemdiabetes.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


